Palimpsest Bio Corp. has announced a new offering under Rule 506(b) of the Securities Act, aiming to raise $1 million through a private investment opportunity. This move is significant for the biotechnology company as it seeks to secure funding for future projects and innovations.

Founded in 2026 and incorporated in Delaware, Palimpsest Bio Corp. is focused on advancing biotechnology solutions. The company, which currently has no revenues, is leveraging private investment avenues to fuel its growth. The recent filing, dated October 30, 2026, indicates that Palimpsest has already raised $172,000 from four investors, with a remaining target of $828,000.

The filing details that the offering is structured as a Simple Agreement for Future Equity (SAFE), which allows investors to convert their investment into equity at a later date. This type of financing is becoming increasingly popular in the biotechnology sector, providing companies with flexibility in raising capital.

According to the filing, the minimum investment accepted is set at $10,000, making it accessible for a range of investors. Notably, the offering does not include any sales commissions or finders' fees, indicating a direct approach to fundraising.

Palimpsest Bio Corp. has indicated that it plans to use approximately $348,000 of the gross proceeds from the offering, although this figure is marked as an estimate. The funds are expected to support the company's operational and developmental needs as it navigates the competitive landscape of biotechnology.

With the biotechnology industry continuously evolving, Palimpsest's decision to pursue private investments reflects broader trends in the sector. Companies are increasingly looking to private offerings as a means to secure funding without the complexities of public markets.

The filing does not specify what steps will follow this offering, leaving investors and stakeholders to anticipate future developments from Palimpsest Bio Corp.